220 related articles for article (PubMed ID: 37351275)
1. Characterization of cuproptosis in gastric cancer and relationship with clinical and drug reactions.
Chen G; Luo D; Qi X; Li D; Zheng J; Luo Y; Zhang C; Ren Q; Lu Y; Chan YT; Chen B; Wu J; Wang N; Feng Y
Front Cell Dev Biol; 2023; 11():1172895. PubMed ID: 37351275
[TBL] [Abstract][Full Text] [Related]
2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X
Front Oncol; 2023; 13():1152681. PubMed ID: 37333810
[TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
Li J; Yin J; Li W; Wang H; Ni B
Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
7. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
Li Y; Zeng X
Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
[No Abstract] [Full Text] [Related]
8. Characterization of a cuproptosis-related signature to evaluate immune features and predict prognosis in colorectal cancer.
Li L; Sun F; Kong F; Feng Y; Song Y; Du Y; Liu F; Kong X
Front Oncol; 2023; 13():1083956. PubMed ID: 37384293
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of a novel cuproptosis-related genes signature associated with prognosis, clinical implications and immunotherapy of hepatocellular carcinoma.
He F; Zeng P; Ma S; Yang X; Liu H; Liu Q; Zhou Y; Zhu H
Front Pharmacol; 2023; 14():1088993. PubMed ID: 36843949
[No Abstract] [Full Text] [Related]
10. Identification of Cuproptosis-Related Subtypes, Establishment of a Prognostic Signature and Characterization of the Tumor Microenvironment in Gastric Cancer.
Li J; Kong C; Song W; Fu T
Int J Gen Med; 2023; 16():1631-1652. PubMed ID: 37168531
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
[TBL] [Abstract][Full Text] [Related]
12. A cuproptosis-related signature for predicting the prognosis of gastric cancer.
He C; Zhang H; Guo Z; Mo Z
J Gastrointest Oncol; 2023 Feb; 14(1):146-164. PubMed ID: 36915443
[TBL] [Abstract][Full Text] [Related]
13. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
14. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer.
Zhang J; Jiang S; Gu D; Zhang W; Shen X; Qu M; Yang C; Wang Y; Gao X
Front Oncol; 2023; 13():1162653. PubMed ID: 37205181
[TBL] [Abstract][Full Text] [Related]
16. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
17. Evaluation the role of cuproptosis-related genes in the pathogenesis, diagnosis and molecular subtypes identification of atherosclerosis.
Wang M; Cheng L; Xiang Q; Gao Z; Ding Y; Xie H; Chen X; Yu P; Shen L
Heliyon; 2023 Oct; 9(10):e21158. PubMed ID: 37928399
[TBL] [Abstract][Full Text] [Related]
18. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
Zhang Y; Zhou J; Li H; Liu Y; Li J
BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
Front Genet; 2023; 14():1094793. PubMed ID: 36891150
[No Abstract] [Full Text] [Related]
20. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
Front Immunol; 2022; 13():933973. PubMed ID: 36045691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]